Eli Lilly's GLP-1 and drug innovation pipeline
The case presented for Eli Lilly hinges on its market-leading GLP-1 franchise and its robust, fast-growing underlying drug pipeline funded by massive cash flow.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.